PFE Pfizer Inc.
PFE Pfizer Inc.
Healthcare · Drug Manufacturers - General
Market read
Scan convergence 1 scan as of 2026-08-14 1 bull converging
POC $23.83 · VWAP $24.54 · +9.5% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 related perspective
PFE Price Structure
Loading timeframes…
Peers
Every watchlist PFE belongs to, members best 30-day change first — PFE highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@healthcare-scan
@healthcare
Pfizer's second-quarter results beat earnings expectations, helped by strong demand for its blood-thinner portfolio, per Reuters (Aug 4 news pull). The company also outlined an additional $2.5 billion in cost cuts to support margins amid ongoing post-pandemic revenue pressure.
full note →Against street estimates
How PFE's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about PFE from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 14 days ago · Aug 4
- Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
- Pfizer Declares Third-Quarter 2026 Dividend
- FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
- Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Pfizer Announces Chief Financial Officer Transition
PFE research tape
30 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.